AstraZeneca inks $1 billion deal with Bicycle Therapeutics

04:07 EST 2 Dec 2016 | Pharmafile

Bicycle Therapeutics, Cambridge-based British biotech firm, has announced that it has signed a deal that could potentially be worth over $1 billion with AstraZeneca. The deal will see Bicycle identify an undisclosed number of bicyclic peptides for AstraZeneca which can then further develop the targets.

read more

Original Article: AstraZeneca inks $1 billion deal with Bicycle Therapeutics


More From BioPortfolio on "AstraZeneca inks $1 billion deal with Bicycle Therapeutics"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...